GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calliditas Therapeutics AB (NAS:CALT) » Definitions » Valuation Rank

Calliditas Therapeutics AB (Calliditas Therapeutics AB) Valuation Rank


View and export this data going back to 2020. Start your Free Trial

What is Calliditas Therapeutics AB Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Calliditas Therapeutics AB Valuation Rank Related Terms

Thank you for viewing the detailed overview of Calliditas Therapeutics AB's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Calliditas Therapeutics AB (Calliditas Therapeutics AB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calliditas Therapeutics AB (NAS:CALT) » Definitions » Valuation Rank
Comparable Companies
OSTO:GENO OSTO:VICO OSTO:EGTX OSTO:HNSA OSTO:IBT B OSTO:FLUO OSTO:BINV OSTO:XSPRAY OSTO:ONCO OSTO:DMYD B OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
CALTX:Sweden CALTXs:UK LC8:Germany
Address
Kungsbron 1, D5, Stockholm, SWE, SE-111 22
Website
https://www.calliditas.se
Calliditas Therapeutics AB is a commercial-stage biopharma company focused on identifying, developing, and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with unmet medical needs. The company's pipeline candidate is TARPEYO medication to reduce proteinuria in IgA nephropathy.